ArticleFrontiers in cellular and infection microbiology2026
Clinical characterization of an
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In 2024, Chile experienced an outbreak of invasive group A Methods: We analyzed 2,307 GAS isolates collected between 2018 and 2024, including 2,249 noninvasive isolates and 58 iGAS isolates. Noninvasive cases were classified as outpatient niGAS or hospitalized niGAS (h-niGAS). Antimicrobial susceptibility testing was performed for all isolates. Results: Among niGAS isolates, 2,119 were obtained from outpatients and 130 from hospitalized patients. h-niGAS isolates showed the highest proportion of clindamycin resistance (42%), whereas iGAS isolates showed the lowest (16%). Notably, clindamycin resistance among iGAS increased from 0% during 2020-2023 to nearly 20% in 2024. The most frequent Discussion: These findings suggest that the Chilean outbreak was driven by the expansion of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.